Kawasaki Disease Coronary Artery Aneurysm Prevention Trial
First site open for patient recruitment into ‘Kawasaki Disease Coronary Artery Aneurysm Prevention trial (KD-CAAP)’ study
The first site is open to recruitment into one of the three inaugural studies which will be utilising the infrastructure and resources of the conect4children network. The IMI conect4children (c4c) consortium is pleased to announce that the first site is now open for the ‘Kawasaki Disease Coronary Artery Aneurysm Prevention trial (KD-CAAP)’ study as of 28 September 2020 at Great Ormond Street Hospital NHS Foundation Trust. Kawasaki disease is a disease where arteries, particularly the coronary arteries in the heart, become inflamed, sometimes causing irreversible heart damage, heart attacks or even death. To prevent heart damage, Kawasaki disease in children and young people must be recognised by clinicians early, and promptly treated with anti-inflammatory medicines.
This study will assess the effectiveness of adding steroids to standard treatment in children with Kawasaki Disease and aims to recruit 262 children as part of the study. The study will continue to open in approximately 60 sites in 15 countries across Europe.
In April 2019, c4c announced the selection of its first portfolio of pan-European paediatric studies, aimed at advancing the understanding of high priority medicines commonly used in babies, children and young people in Europe. The KD-CAAP study is the first of the proof of viability studies, to begin recruitment. The other academic studies, shown below, plan to begin recruitment later this year, despite initial delays due to the COVID-19 pandemic.